The characteristics of CIK cells and the research progress in immune therapy of digestive system tumors

doi:10.3877/cma.j.issn.2095-3224.2017.01.011

Abstract

Abstract:

Tumor adoptive cellular immunotherapy is a new tumor treatment technology, is following the traditional surgery, chemotherapy, radiation therapy, and treatment of tumor treatment methods, such as model, has been named by Science for first ten major breakthrough in 2013. Of cytokine induced killer cells (cytokine induced killer cells, CIK cells) because of its uniqueness, feasibility, effectiveness and safety, etc., has become the preferred scheme of tumor immunotherapy, but CIK cells killing mechanism is not fully clear, and CIK cell treatment technology is still in the clinical trials, remains to be further in-depth study and the breakthrough, this paper from the biological characteristics of CIK cells, killing mechanism and CIK cells on the basis of digestive system tumors and summarized the research progress of clinical application of several aspects.

Key words: Digestive system, Immunotherapy, CIK cells

Zhengqun Zhang, Xinggang Ma. The characteristics of CIK cells and the research progress in immune therapy of digestive system tumors[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(01): 52-55.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2017.01.011

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2017/V06/I01/52

References 34

[1]	Pievani A, Borleri G, Pende D, et al. Dual-functional capability of CD3^＋CD56^＋CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity [J]. Blood, 2011, 118(12): 3301-3310.
[2]	Zhang YS, Yuan FJ, Jia GF, et al. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R [J]. World J Gastroenterol, 2005, 11(22): 3339-3345.
[3]	Sangiolo D, Mesiano G, Gammaitoni L, et al. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas [J]. Cancer Res, 2014, 74(1): 119-129.
[4]	Tao Q, Chen T, Tao L, et al. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3^＋CD56^＋ cells and downregulating regulatory T cells as well as IL-35 [J]. J Immunother, 2013, 36(9): 462-467.
[5]	Rajbhandary S, Zhao MF, Zhao N, et al. Multiple cytotoxic factors involved in IL-21 enhanced antitumor function of CIK cells signaled through STAT-3 and STAT5b pathways [J]. Asian Pac J Cancer Prev, 2013, 14(10): 5825-5831.
[6]	Kim HM, Lim J, Yoon YD, et al. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma [J]. Int Immunopharmacol, 2007, 7(13): 1793-1801.
[7]	Linn YC, Lau SK, Liu BH, et al. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell [J]. Immunology, 2009, 126(3): 423-435.
[8]	Franceschetti M, Pievani A, Borleri G, et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes [J]. Exp Hematol, 2009, 37(5): 616-628.e2.
[9]	Brinkmann OA, Bruns F, Gosheger G, et al. Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation [J]. World J Urol, 2005, 23(3): 185-190.
[10]	何金媛，贾祝霞，蔡晓辉, 等. NKG2D在细胞因子诱导的杀伤性细胞(CIK)抗血液肿瘤细胞的作用 [J]. 中国实验血液学杂志, 2013, 21(6): 1380-1384.
[11]	Bahram S, Shiina T, Oka A, et al. Genomic structure of the human MHC class I MICB gene [J]. Immunogenetics, 1996, 45(2): 161-162.
[12]	Xu X, Rao GS, Groh V, et al. Major histocompatibility complex class I-related chain A/B(MICA/B)expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression [J]. BMC Cancer, 2011, 11: 194.
[13]	Bae JH, Kim SJ, Kim MJ, et al. Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction [J]. Cancer Sci, 2012, 103(1): 7-16.
[14]	Mehta BA, Schmidt-Wolf IG, Weissman IL, et al. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3^＋ CD56^＋ killer cells [J]. Blood, 1995, 86(9): 3493-3499.
[15]	Kuçi S, Rettinger E, Voss B, et al. Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation [J]. Haematologica, 2010, 95(9): 1579-1586.
[16]	李花，孙抒，杨万山, 等. CIK细胞对A549肺癌细胞株的诱导凋亡作用的研究 [J]. 实用肿瘤杂志, 2011, 26(4): 356-359.
[17]	孙抒，李雪梅，王建光, 等. CIK细胞对MGC-803胃癌细胞株抗增殖及诱导凋亡作用的研究 [J]. 中国免疫学杂志, 2004, 20(12): 831-833, 837.
[18]	庞佳楠，崔久嵬. 细胞因子诱导的杀伤细胞治疗肿瘤的研究进展 [J]. 中华临床医师杂志(电子版), 2014, 8(15): 2889-2893.
[19]	Kim YJ, Lim J, Kang JS, et al. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells [J]. Arch Pharm Res, 2010, 33(11): 1789-1795.
[20]	Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer [J]. Cancer Immunol Immunother, 2012, 61(12): 2251-2259.
[21]	Tumeh PC, Koya RC, Chodon T, et al. The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy [J]. J Immunother, 2010, 33(8): 759-768.
[22]	Huang J, Li C, Wang Y, et al. Cytokine-induced killer(CIK)cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high)cancer stem cells in vitro and in vivo [J]. Clin Immunol, 2013, 149(1): 156-168.
[23]	刘洪一，李荣，刘巨超, 等. 双特异性单抗对胃肠癌的体内杀伤作用 [J]. 实用临床医药杂志, 2012, 16(5): 19-22.
[24]	王美梅，张南征，陈复兴, 等. 白桦酯酸对人CIK细胞杀伤胃癌细胞株SGC-7901的功能影响及机制研究 [J]. 中华微生物学和免疫学杂志, 2012, 32(1): 48-53.
[25]	Yu X, Xia W, Zhang T, et al. Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells [J]. Int J Hematol, 2010, 92(2): 276-282.
[26]	陈艳，刘辉，于丽, 等. 表达新型干扰素的CIK细胞对结肠癌的治疗作用 [J]. 中华实验外科杂志, 2011, 28(12): 2158-2161.
[27]	Li XD, Xu B, Wu J, et al. Review of Chinese clinical trials on CIK cell treatment for malignancies [J]. Clin Transl Oncol, 2012, 14(2): 102-108.
[28]	Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer [J]. Cancer Immunol Immunother, 2012, 61(12): 2251-2259.
[29]	Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy [J]. Oncologist, 2002, 7(Suppl 4): 2-8.
[30]	李建旺，彭大为，黄春珍, 等. 自体CIK细胞及DC细胞联合索拉非尼治疗晚期肝癌的临床观察 [J]. 实用癌症杂志, 2011, 26(5): 459-461.
[31]	Ramakrishnan R, Assudani D, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice [J]. J Clin Invest, 2010, 120(4): 1111-1124.
[32]	李辉，毛伟征，安岗, 等. 细胞因子诱导杀伤细胞杀伤胃癌的特异性与非特异性研究 [J]. 中华实验外科杂志, 2010, 27(4): 428-430.
[33]	Huang ZM, Li W, Li S, et al. Cytokine-induced Killer Cells in Combination With Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Patients [J]. J Immunother, 2013, 36(5): 287-293.
[34]	Wang XP, Xu M, Gao HF, et al. Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma [J]. World J Gastroenterol, 2013, 19(19): 2956-2962.

Please choose a citation manager

Content to export